World Conference on Lung Cancer

image of two race cars neck and neck
Biotech

Daiichi, Merck rev up for accelerated approval filing

“The important take-home message is that this is our registrational trial for the first approval of the drug I-DXd,” Daiichi’s Ken Takeshita said.
Gabrielle Masson Sep 7, 2025 10:45am
amgen

Amgen touts early combo data with Sanofi-backed KRAS partner

Jul 12, 2022 7:30pm
Janssens Beerse campus

J&J's bispecific curbs 74% of lung cancers with rare mutation

Jan 28, 2021 10:45pm
Amgen Headquarters

Amgen's KRAS drug pads its case for approval

Jan 28, 2021 4:47pm